To compare the relative efficacies of two different doses of aspirin taken daily on a long-term basis in the secondary prevention of stroke.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
Randomized, double-blind, placebo-controlled trial of 2435 patients at 33 centers.
Patients were randomized to receive either aspirin two 300 mg tablets twice daily, aspirin two 150 mg tablets once daily and placebo once daily, or placebo twice daily. If patients complained of indigestion they were advised to omit the second daily dose of tablets. If they still complained of indigestion, they were told to take just one tablet of the first daily dose. If indigestion persisted, they were advised to transfer to enteric coated trial medication and if necessary reduce dose to one tablet daily. Patients were seen every 4 months until the scheduled end of the trial or prior death or emigration. If they were not able or willing to go the neurological clinics for follow-up, their general practitioners were contacted for information. Treatment was continued for an average of four years range .
|Type||Measure||Time Frame||Safety Issue|
|Primary||Time to composite event of major stroke (modified Rankin scale score >=3), myocardial infarction or vascular death.|